Analystreport

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) had its "buy" rating re-affirmed by analysts at Laidlaw. They now have a $7.50 price target on the stock.

ZIOPHARM Oncology Inc  (ZIOP) 
Last ziopharm oncology inc earnings: 3/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ziopharm.com